Safety issues pinpointed earlier with Spotfire's interactive analysis data solution
Safety issues pinpointed earlier with Spotfire's interactive analysis data solution
Spotfire's (Somerville, MA) Clinical Trial Analysis software is built on its DXP enterprise analytics platform for pharmaceutical companies and can be used by physicians, scientists, analysts, and nontechnical staff to discover data relationships related to drug safety and efficacy. This allows companies to address drug design and discovery earlier in the process.
Spotfire Clinical Trial Analysis provides querying capabilities of clinical and molecular data using graphs and charts. It analyzes data from various sources to identify trends, outliers, and exceptions; offers visual representations (charts, plots, graphs) of adverse event data, lab safety, demographics, and concomitant medications; allows for ad hoc data query; finds correlations between gene or protein expressions and safety profiles; and adapts to new technologies and methodologies.
Spotfire, (617) 702-1600, www.spotfire.com
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.